AVP-21D9

DB17798InvestigationalProtein Based Therapies

AVP-21D9 is a fully human anthrax monoclonal antibody that is being investigated as an anthrax antitoxin.

Mechanism
Curator reviewed
Also known as
AVP 21D9 · AVP 22G12 · AVP 8C1 · AVP-22G12 · AVP-3E7/G3

Resolves to

Compound
UNII6RUU8A4K0R
Targets
P13423pagA

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
1Clinical trialPhase, status and sponsor resolved per trial
Sign in
3+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with AVP-21D9, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In